MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.esmoop.2026.108313

Медицинская библиотека · ESMO open · 2026

Cancer treatments-related factors for subsequent soft-tissue sarcoma in childhood cancer survivors.

Allodji R S, Reulen R C, Diallo I, Winter D L, Vu-Bezin G, Bolle S, Locquet M, Bagnasco F, Bárdi E, Feijen E A M, Alessi D, Fidler-Benaoudia M M, Høgsholt S, Bright C J, Linge H, Fresneau B, Haddy N, Veres C, Llanas D, Journy N, Demoor-Goldschmidt C, Byrne J, Bejarano-Quisoboni D, Grabow D, Zrafi W, Gudmundsdottir T, Michel G, Gunnes W, Kaatsch P, Rubino C, Jenkinson H, Kaiser M, Skinner R, Aho Glele R, Ducos C, Aba N, Cole T, Waespe N, Nordenfelt S, Charrier T, Zidane M, Jankovic M, Lähteenmäki T, Maule M M, van der Pal H J H, Ronckers C M, van Leeuwen F E, Teepen J, Terenziani M, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki P M, Zadravec Zaletel L, Kuehni C E, Winther J F, Kremer L C, Hjorth L, Hawkins M M, de Vathaire F

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Previous studies of risk factors for subsequent soft-tissue sarcoma (STS) among childhood cancer survivors had small numbers and were unable to comprehensively investigate the dose-response relationships with radiation from radiotherapy and with cumulative exposure to specific cytotoxics.

PATIENTS AND

METHODS

We conducted a nested case-control study, encompassing 275 subsequent STS cases and 275 matched controls, within the Pan-European cohort of 69 460 5-year survivors from 12 countries. Odds ratios (ORs) and 95% confidence intervals (CIs) for subsequent STS were calculated for different levels of radiation dose to the STS location (in Gy) and for cumulative doses of specific chemotherapeutic agents (in g/m2). Additionally, excess ORs per Gy (EOR/Gy) or per g/m2 (EOR/g/m2) were calculated to assess dose-response relationships.

RESULTS

The OR for subsequent STS was 22-fold [95% CI 6.9-95.4] higher in soft tissue exposed to ≥30 Gy and remained in excess with exposure to 5-9 Gy [OR = 3.8, 95% CI 1.3-12.0] compared with no radiation. The EOR/Gy was 0.86 [95% CI 0.35-2.16], with a particularly high risk observed in survivors of neuroblastoma [EOR/Gy = 5.52, 95% CI 0.71-52.31] or bone sarcoma [EOR/Gy = 4.16, 95% CI 0.40-24.72], and in females [EOR/Gy = 2.35; 95% CI 0.65-8.14]. For patients who had received a cumulative procarbazine dose of ≥6.0 g/m2, the OR was 4.7 [95% CI 1.3-25.1] compared with non-exposure after controlling for radiation. No association was found for other alkylating agents or other specific cytotoxic drugs.

CONCLUSION

Although high radiation doses remain the primary risk factor for secondary STS, our findings suggest a possible increase in risk at lower doses (5-9 Gy) and following procarbazine treatment among childhood cancer survivors. These observations warrant further investigation and may merit consideration in treatment planning and long-term follow-up guidelines for cancer survivors.

Для цитирования: Allodji R S, Reulen R C, Diallo I, Winter D L, Vu-Bezin G, Bolle S, Locquet M, Bagnasco F, Bárdi E, Feijen E A M, Alessi D, Fidler-Benaoudia M M, Høgsholt S, Bright C J, Linge H, Fresneau B, Haddy N, Veres C, Llanas D, Journy N, Demoor-Goldschmidt C, Byrne J, Bejarano-Quisoboni D, Grabow D, Zrafi W, Gudmundsdottir T, Michel G, Gunnes W, Kaatsch P, Rubino C, Jenkinson H, Kaiser M, Skinner R, Aho Glele R, Ducos C, Aba N, Cole T, Waespe N, Nordenfelt S, Charrier T, Zidane M, Jankovic M, Lähteenmäki T, Maule M M, van der Pal H J H, Ronckers C M, van Leeuwen F E, Teepen J, Terenziani M, Wiebe T, Sacerdote C, Jakab Z, Haupt R, Lähteenmäki P M, Zadravec Zaletel L, Kuehni C E, Winther J F, Kremer L C, Hjorth L, Hawkins M M, de Vathaire F. Cancer treatments-related factors for subsequent soft-tissue sarcoma in childhood cancer survivors.. ESMO open. 2026. DOI: 10.1016/j.esmoop.2026.108313.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.